341 related articles for article (PubMed ID: 23459241)
1. Diabetic retinopathy and VEGF.
Gupta N; Mansoor S; Sharma A; Sapkal A; Sheth J; Falatoonzadeh P; Kuppermann B; Kenney M
Open Ophthalmol J; 2013; 7():4-10. PubMed ID: 23459241
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
3. The Evolving Treatment of Diabetic Retinopathy.
Mansour SE; Browning DJ; Wong K; Flynn HW; Bhavsar AR
Clin Ophthalmol; 2020; 14():653-678. PubMed ID: 32184554
[TBL] [Abstract][Full Text] [Related]
4. Current intravitreal pharmacologic therapies for diabetic macular edema.
Colucciello M
Postgrad Med; 2015 Aug; 127(6):640-53. PubMed ID: 26036708
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab for the management of diabetic macular edema.
Stefanini FR; Arevalo JF; Maia M
World J Diabetes; 2013 Apr; 4(2):19-26. PubMed ID: 23593532
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Evans JR
Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature.
Chatziralli I; Loewenstein A
Pharmaceutics; 2021 Jul; 13(8):. PubMed ID: 34452097
[No Abstract] [Full Text] [Related]
8. Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
Ajlan RS; Silva PS; Sun JK
Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128
[TBL] [Abstract][Full Text] [Related]
9. Risk of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice.
Maloney MH; Schilz SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2019 Jul; 126(7):1007-1015. PubMed ID: 30292542
[TBL] [Abstract][Full Text] [Related]
10. A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.
Stewart MW
Ophthalmol Ther; 2017 Jun; 6(1):33-47. PubMed ID: 28324452
[TBL] [Abstract][Full Text] [Related]
11. [Choice of treatment for diabetic macular edema].
Yang L; Zhang J
Zhonghua Yan Ke Za Zhi; 2017 Oct; 53(10):724-728. PubMed ID: 29050184
[TBL] [Abstract][Full Text] [Related]
12. Critical appraisal of ranibizumab in the treatment of diabetic macular edema.
Stewart MW
Clin Ophthalmol; 2013; 7():1257-67. PubMed ID: 23836955
[TBL] [Abstract][Full Text] [Related]
13. Current and Future Pharmacologic Therapies for Diabetic Retinopathy.
Villegas VM; Schwartz SG
Curr Pharm Des; 2018; 24(41):4903-4910. PubMed ID: 30706803
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Brunetti M
Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
[TBL] [Abstract][Full Text] [Related]
15. Current treatment modalities in diabetic macular edema.
Choragiewicz T; Ozimek M; Nowomiejska K; Koss MJ; Juenemann AGM; Rejdak R
Klin Oczna; 2016 Sep; 117(4):267-270. PubMed ID: 29727116
[TBL] [Abstract][Full Text] [Related]
16. A multimodal approach to diabetic macular edema.
Au A; Singh RP
J Diabetes Complications; 2016 Apr; 30(3):545-53. PubMed ID: 26853628
[TBL] [Abstract][Full Text] [Related]
17. Diabetic retinopathy, diabetic macular edema, and cardiovascular risk: the importance of a long-term perspective and a multidisciplinary approach to optimal intravitreal therapy.
Bandello F; Toni D; Porta M; Varano M
Acta Diabetol; 2020 May; 57(5):513-526. PubMed ID: 31749046
[TBL] [Abstract][Full Text] [Related]
18. Clinical practice pattern in management of diabetic macular edema in Japan: survey results of Japanese retinal specialists.
Ogura Y; Shiraga F; Terasaki H; Ohji M; Ishida S; Sakamoto T; Hirakata A; Ishibashi T
Jpn J Ophthalmol; 2017 Jan; 61(1):43-50. PubMed ID: 27722786
[TBL] [Abstract][Full Text] [Related]
19. The impact of anti-vascular endothelial growth factor agents on visual impairment/blindness prevention in patients with diabetic macular edema and on associated patient and caregiver burden in Japan.
Kitano S; Sakamoto T; Goto R; Fukushima A; Vataire AL; Hikichi Y
J Med Econ; 2019 Mar; 22(3):254-265. PubMed ID: 30550375
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor and diabetic macular edema.
Lally DR; Shah CP; Heier JS
Surv Ophthalmol; 2016; 61(6):759-768. PubMed ID: 27045225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
